CellaVision AB (CEVI) - Total Liabilities
Based on the latest financial reports, CellaVision AB (CEVI) has total liabilities worth Skr207.31 Million SEK (≈ $22.31 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CellaVision AB - Total Liabilities Trend (2000–2025)
This chart illustrates how CellaVision AB's total liabilities have evolved over time, based on quarterly financial data. See CellaVision AB current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CellaVision AB Competitors by Total Liabilities
The table below lists competitors of CellaVision AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Elitegroup Computer Systems Co Ltd
TW:2331
|
Taiwan | NT$11.99 Billion |
|
Kirloskar Industries Limited
NSE:KIRLOSIND
|
India | Rs35.24 Billion |
|
Qingdao Hi-Tech Moulds & Plastics Technology Co. Ltd.
SHE:301022
|
China | CN¥805.15 Million |
|
Dingdong (Cayman) Limited ADR
NYSE:DDL
|
USA | $5.58 Billion |
|
Shinsegae Inte
KO:031430
|
Korea | ₩567.22 Billion |
|
Gladstone Land Corporation
NASDAQ:LAND
|
USA | $568.89 Million |
|
Gravity Co. Ltd
F:GD8A
|
Germany | €105.30 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down CellaVision AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CellaVision AB (CEVI) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CellaVision AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CellaVision AB (2000–2025)
The table below shows the annual total liabilities of CellaVision AB from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr207.31 Million ≈ $22.31 Million |
+5.68% |
| 2024-12-31 | Skr196.16 Million ≈ $21.11 Million |
-7.61% |
| 2023-12-31 | Skr212.32 Million ≈ $22.85 Million |
-15.11% |
| 2022-12-31 | Skr250.12 Million ≈ $26.92 Million |
-11.28% |
| 2021-12-31 | Skr281.93 Million ≈ $30.34 Million |
+18.26% |
| 2020-12-31 | Skr238.41 Million ≈ $25.66 Million |
-18.73% |
| 2019-12-31 | Skr293.34 Million ≈ $31.57 Million |
+255.96% |
| 2018-12-31 | Skr82.41 Million ≈ $8.87 Million |
+37.93% |
| 2017-12-31 | Skr59.75 Million ≈ $6.43 Million |
+18.85% |
| 2016-12-31 | Skr50.27 Million ≈ $5.41 Million |
+36.20% |
| 2015-12-31 | Skr36.91 Million ≈ $3.97 Million |
-27.56% |
| 2014-12-31 | Skr50.95 Million ≈ $5.48 Million |
-9.11% |
| 2013-12-31 | Skr56.06 Million ≈ $6.03 Million |
+4.50% |
| 2012-12-31 | Skr53.64 Million ≈ $5.77 Million |
+1.87% |
| 2011-12-31 | Skr52.66 Million ≈ $5.67 Million |
+7.30% |
| 2010-12-31 | Skr49.08 Million ≈ $5.28 Million |
+27.30% |
| 2009-12-31 | Skr38.55 Million ≈ $4.15 Million |
-23.64% |
| 2008-12-31 | Skr50.49 Million ≈ $5.43 Million |
+109.95% |
| 2007-12-31 | Skr24.05 Million ≈ $2.59 Million |
+1.92% |
| 2006-12-31 | Skr23.60 Million ≈ $2.54 Million |
+19.90% |
| 2005-12-31 | Skr19.68 Million ≈ $2.12 Million |
-27.03% |
| 2004-12-31 | Skr26.97 Million ≈ $2.90 Million |
+20.07% |
| 2003-12-31 | Skr22.46 Million ≈ $2.42 Million |
-10.24% |
| 2002-12-31 | Skr25.02 Million ≈ $2.69 Million |
-23.58% |
| 2001-12-31 | Skr32.74 Million ≈ $3.52 Million |
+79.77% |
| 2000-12-31 | Skr18.21 Million ≈ $1.96 Million |
-- |
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more